Published in Pediatr Nephrol on December 10, 2008
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest (1998) 1.80
T cell antigen-receptor signal transduction. Curr Opin Immunol (1999) 1.68
Lymphocyte function in wound healing and following injury. Br J Surg (1998) 1.42
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
Upregulation of renal BSC1 and TSC in prenatally programmed hypertension. Am J Physiol Renal Physiol (2002) 1.26
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun (1998) 1.10
Arginine and immune function. Nutrition (1992) 1.07
L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res (2001) 1.06
Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. Pediatr Nephrol (1994) 1.01
T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol (1997) 0.98
Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol (1998) 0.95
Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology (2001) 0.91
Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health (2004) 0.85
Evaluation of T lymphocyte subpopulations in children with nephrotic syndrome. Clin Exp Immunol (1983) 0.83
Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol (1998) 0.82
Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients. Am J Nephrol (2007) 0.81
Infections in children with nephrotic syndrome. J Coll Physicians Surg Pak (2003) 0.79
Multiple serum inhibitors of lectin-induced lymphocyte proliferation in nephrotic syndrome. Clin Exp Immunol (1981) 0.78
Decreased expression of T-cell NF-kappaB p65 subunit in steroid-resistant nephrotic syndrome. Kidney Int (2004) 0.77
Serum levels of C3 and factors I and B in minimal change disease. Acta Paediatr Jpn (1998) 0.76
[Bacterial complications of nephrotic syndrome in children]. Presse Med (1995) 0.75
Bactericidal activity of ascitic fluid in patients with nephrotic syndrome. Eur J Clin Invest (1985) 0.75
Altered in vitro lymphocyte response in childhood nephrotic syndrome. Pediatr Nephrol (1992) 0.75
[Expression of zeta (zeta) chain in peripheral blood T lymphocytes and NK cells of children with idiopathic nephrotic syndrome (INS)--preliminary results]. Przegl Lek (2006) 0.75
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis (2006) 1.53
Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 1.46
L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol (2005) 1.45
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). J Immunol (2004) 1.37
Kidney angiotensin and angiotensin receptor expression in prenatally programmed hypertension. Am J Physiol Renal Physiol (2004) 1.28
Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant (2013) 1.21
T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol (2005) 1.16
Purification and characterization of Helicobacter pylori arginase, RocF: unique features among the arginase superfamily. Eur J Biochem (2004) 1.16
Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother (2007) 1.15
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer (2010) 1.15
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int (2005) 1.10
Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis (2009) 1.09
In vitro and in vivo complementation of the Helicobacter pylori arginase mutant using an intergenic chromosomal site. Helicobacter (2006) 1.07
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol (2010) 1.06
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer (2013) 1.04
Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol (2006) 1.04
Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis (2008) 1.03
Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am J Physiol Regul Integr Comp Physiol (2002) 1.01
Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol (2006) 0.95
Adolescent alcohol use in context: the role of parents and peers among African American and European American youth. Cultur Divers Ethnic Minor Psychol (2008) 0.94
Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. J Immunol (2010) 0.93
Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells. Infect Immun (2011) 0.93
Mechanisms of tumor evasion. Cancer Treat Res (2005) 0.90
Nursing bedside clinical handover - an integrated review of issues and tools. J Clin Nurs (2014) 0.87
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther (2011) 0.86
Effect of hyperosmolality on beta-defensin gene expression by human corneal epithelial cells. Cornea (2006) 0.85
The great mimicker: IgG4-related disease. Clin Rheumatol (2013) 0.84
Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase. J Biol Chem (2012) 0.84
Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei. PLoS Negl Trop Dis (2013) 0.83
Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif (2003) 0.83
Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains. J Virol (2009) 0.81
Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma. J Hematol Oncol (2008) 0.81
Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci (2012) 0.80
Real-time PCR for quantification of Helicobacter felis in mouse stomach. South Med J (2006) 0.80
Association of haplotypes of inflammation-related genes with gastric preneoplastic lesions in African Americans and Caucasians. Int J Cancer (2011) 0.80
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. J Oncol Pharm Pract (2013) 0.79
Polycyclic aromatic hydrocarbons-induced ROS accumulation enhances mutagenic potential of T-antigen from human polyomavirus JC. J Cell Physiol (2013) 0.79
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer (2014) 0.78
Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother (2011) 0.78
Effect of L-arginine supplementation on immune responsiveness in patients with sickle cell disease. Pediatr Blood Cancer (2010) 0.77
Decreased expression of T-cell NF-kappaB p65 subunit in steroid-resistant nephrotic syndrome. Kidney Int (2004) 0.77
Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors. Clin Rheumatol (2014) 0.76
The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. Antiviral Res (2013) 0.75
Talking about the creative use of enhancements. Nature (2008) 0.75
Creating a Research Agenda and Setting Research Priorities for Clinical Nurse Specialists. Clin Nurse Spec (1) 0.75